Reviews critical issues (e.g., endpoint/margin selection, sample
size requirement and complex innovative design). Provides better
understanding of statistical concepts and methods which may be used
in regulatory review and approval. Clarifies controversial
statistical issues in regulatory review and approval. Makes
recommendations to accurately and reliably evaluate rare diseases
regulatory submissions. Proposes innovative study designs and
statistical methods for rare diseases drug development including
n-of-1 trial design, adaptive trial design, and master protocols
such as platform trials. Provides insight regarding current
regulatory guidance on rare diseases drug development such as gene
therapy.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!